NCT00002326
Completed
Phase 1
A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of Combination Zidovudine (AZT) and 9-(2-Phosphonylmethoxyethyl)Adenine (PMEA; Adefovir) Treatment in HIV-Infected Patients
ConditionsHIV Infections
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- HIV Infections
- Sponsor
- Gilead Sciences
- Enrollment
- 20
- Locations
- 1
- Status
- Completed
- Last Updated
- 20 years ago
Overview
Brief Summary
To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of combination zidovudine (AZT) and PMEA (adefovir) therapy.
Detailed Description
Patients receive AZT daily and intravenous PMEA three times weekly for 4 weeks. An MTD will be defined for this regimen.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV DrugsHIV InfectionsNCT00001067National Institute of Allergy and Infectious Diseases (NIAID)105
Completed
Phase 1
A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV DiseaseHIV InfectionsNCT00000814National Institute of Allergy and Infectious Diseases (NIAID)390
Completed
Phase 1
A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV DiseaseHIV InfectionsNCT00000696National Institute of Allergy and Infectious Diseases (NIAID)48
Completed
Not Applicable
A Study of Zidovudine and T Lymphocyte Transfer in the Treatment of HIV Type III in Patients With AIDSHIV InfectionsNCT00002285Glaxo Wellcome
Completed
Phase 1
The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected PatientsHIV InfectionsNCT00002346Gilead Sciences36